Instil Bio rises on resuming cancer therapy trial

Instil Bio

09/01/2023 13:53

** Instil Bio Inc shares  TIL.O  rise 13% to 72 cents in
premarket trade
    ** Co resumes early-stage trial of experimental therapy
ITIL-306 in non-small cell lung cancer, ovarian cancer and
kidney cancer after voluntary pause
    ** Initial data readout expected in 2023 - co
    ** Due to recent restructuring, co expects cash runway into
2025
    ** Two of five brokerages rate the stock "strong buy" and
three "hold"; their median PT is $5 - Refinitiv
    ** Stock slumped 96% in 2022
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))